Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials

To investigate the cause of visual acuity (VA) loss in patients with neovascular age-related macular degeneration (AMD) receiving monthly ranibizumab injections in the pivotal ranibizumab phase III trials. Retrospective analysis. The Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizum...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 118; no. 3; p. 523
Main Authors:	Rosenfeld, Philip J, Shapiro, Howard, Tuomi, Lisa, Webster, Mary, Elledge, Julee, Blodi, Barbara
Format:	Journal Article
Language:	English
Published:	United States 01.03.2011
Subjects:	Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology Fluorescein Angiography Humans Intravitreal Injections Macular Degeneration - drug therapy Macular Degeneration - physiopathology Ranibizumab Retinal Pigment Epithelium - pathology Retrospective Studies Risk Factors Tomography, Optical Coherence Vascular Endothelial Growth Factor A - antagonists & inhibitors Vision Disorders - physiopathology Visual Acuity - physiology
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!